Optimization · Active
Working on it together since March 2026
The current work is a deliberate dose taper, from 300 mg toward 100 mg, testing whether a lower maintenance dose holds most of the...
Hold the reduced dose and watch the relevant metabolic markers, fasting glucose, blood pressure, and uric acid, to confirm...
One line of work is active.
SGLT2 inhibition with canagliflozin confers cardio-renal and longevity benefits, improved glucose handling, favorable blood-pressure and uric-acid effects, and...
Nothing separate from the story cards right now.
Hold the reduced dose and watch the relevant metabolic markers, fasting glucose, blood pressure, and uric acid, to confirm...